Top 10 most-read posts of July
Being a scientist and writer of a science blog, one can’t help being mesmerized by the statistics behind one’s readership. Over the last five years I’ve been quite surprised to see what posts garner a large number of readers and comments and which ones don’t (more often those that take a lot of time to write).
As posts gain traction among Google search returns on popular topics, you’ll often see http://www.adinfusion.com/ continuing to be among the most-read for months after writing.
So here are some data for you as well as a nice list of posts that you may have missed first time around:
1. iAroma synthetic marijuana and the loss of Max Dobner – 16 July 2011 – 1,022 views, 4 comments
2. DEA already admits defeat on synthetic marijuana ban? – 02 March 2011 – 833 views, 23 comments
3. Flurry of FDA action against aromatase supplements – 27 September 2010 – 490 views, 5 comments
4. Amy Winehouse found dead in London – 23 July 2011 – 395 views, 3 comments
5. What’s the buzz?: Synthetic marijuana, K2, Spice, JWH-018 (repost) – 07 September 2010 – 352 views, 20 comments
6. SciAm blog network follow-up – 11 July 2011 – 324 views, 12 comments
7. Welcome Scientific American blog network! – 05 July 2011 – 307 views, 17 comments
8. Fingolimod (Gilenya, Novartis) for multiple sclerosis – 11 May 2011 – 249 views, 2 comments
9. “Synthetic marijuana” chemist John W Huffman interviewed on regional NPR program – 26 January 2011 – 187 views, 2 comments
10. Poppy seed tea can kill you (repost) – 13 April 2011 – 185 views, 2 comments
A few interesting observations:
- Only four of the top ten most-read posts in July were actually authored in July
- Two posts weren’t even written this year
- Four posts dealt with some aspect of synthetic marijuana chemistry and pharmacology
- Three posts dealt with death
- Two posts dealt with the blogging community
- Synthetic marijuana users and bloggers are most likely to comment on blogposts about them
And which one surprises me the most? The post on aromatase inhibitors being in dietary supplements. These agents, developed originally to treat breast cancer, have found increasing use in bodybuilding and in testosterone-deficiency of aging (now called “low-T” in pharma commercials). The post hasn’t drawn a comment since November but “aromatase inhibitors” remain one of the top search terms that bring readers to the blog. I’m not sure if those readers are seeking information on breast cancer or testosterone replacement therapy.
Happy analyzing, reading, or re-reading!